Tapentadol

Results: 167



#Item
131NDA[removed]S002 Page 3 Sanctura® (trospium chloride) 20 mg Tablets PRESCRIBING INFORMATION DESCRIPTION

NDA[removed]S002 Page 3 Sanctura® (trospium chloride) 20 mg Tablets PRESCRIBING INFORMATION DESCRIPTION

Add to Reading List

Source URL: www.fda.gov

Language: English
132Imitrex summary FINAL.doc

Imitrex summary FINAL.doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-11-17 09:59:32
133C:�a�Documents�rlecit MO Executive Summary.doc

C:aDocumentsrlecit MO Executive Summary.doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-11-17 09:59:28
134C:�a�a�view�iflu�SLR_exclusivity.doc

C:aaviewifluSLR_exclusivity.doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-11-17 09:59:21
135M:�a�ILES�plar�ExSummary_zemplar.doc

M:aILESplarExSummary_zemplar.doc

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-06-28 09:23:55
136Approval Date: August 21, 2002  FREEDOM OF INFORMATION SUMMARY NADA[removed]DERAMAXX™ Chewable Tablets

Approval Date: August 21, 2002 FREEDOM OF INFORMATION SUMMARY NADA[removed]DERAMAXX™ Chewable Tablets

Add to Reading List

Source URL: www.fda.gov

Language: English
137Approval Date: April 2, 2003  FREEDOM OF INFORMATION SUMMARY Supplemental NADA

Approval Date: April 2, 2003 FREEDOM OF INFORMATION SUMMARY Supplemental NADA

Add to Reading List

Source URL: www.fda.gov

Language: English
138Public Meeting on the Class-Wide ER/LA Opioid Analgesics Postmarketing Requirements Discussion Topics for Postmarketing Requirement (PMR) 5 Discussion Topic #1 An important premise of the proposed study to respond to Pos

Public Meeting on the Class-Wide ER/LA Opioid Analgesics Postmarketing Requirements Discussion Topics for Postmarketing Requirement (PMR) 5 Discussion Topic #1 An important premise of the proposed study to respond to Pos

Add to Reading List

Source URL: www.fda.gov

Language: English
139[removed]Federal Register / Vol. 79, No[removed]Tuesday, April 22, [removed]Notices we expect that about 5% of participants taking the pre-choice survey will not return to participate in the experiment

[removed]Federal Register / Vol. 79, No[removed]Tuesday, April 22, [removed]Notices we expect that about 5% of participants taking the pre-choice survey will not return to participate in the experiment

Add to Reading List

Source URL: www.gpo.gov

Language: English - Date: 2014-04-30 14:41:12
140NEW HAMPSHIRE MEDICAID PHARMACY PROGRAM New Hampshire TO:

NEW HAMPSHIRE MEDICAID PHARMACY PROGRAM New Hampshire TO:

Add to Reading List

Source URL: www.dhhs.nh.gov

Language: English - Date: 2010-10-25 15:18:33